Development of cancer therapy-related cardiac dysfunction in anthracycline-treated breast cancer patients: a retrospective study Authors: Junko Kuroda, Masayoshi Oikawa, Emi Tokuda, Kazunoshin Tachibana, Eisaku Sasaki, Tohru Ohtake, Yasuchika Takeishi, Shigehira Saji Published: 2024 ABSTRACT PurposeCardiac dysfunction as a result of anthracycline treatment is a major concern regarding the management of patient life after therapy. The aim of the present study was to determine the clinical characteristics of cancer patients at high risk of developing cancer therapy-related cardiac dysfunction (CTRCD), in order to improve the risk management for the appropriate treatment.MethodsThis is a single-center, retrospective study of patients with breast cancer who underwent anthracycline treatment and had regular consultations with cardiologists. To investigate the incidence of CTRCD and the risk factors related to its occurrence, left ventricular ejection fraction (LVEF), cardiac troponin I (TnI), and brain natriuretic peptide (BNP) were assessed in 177 patients at the start of anthracycline treatment, and again at 3, 6, 9, and 12 months.ResultsEight patients (4.5%) developed CTRCD (CTRCD group). The comparisons between the CTRCD group and those without CTRCD (non-CTRCD group) showed significant differences in pre-treatment cancer stage and neutrophil/lymphocyte ratio (NLR). Multivariate analysis showed a strong association between pre-treatment cancer stage, NLR, and type of anthracycline administered (epirubicin or doxorubicin).ConclusionHigh NLR, the more advanced stages of cancer, and doxorubicin administration were suggested as possible risk factors for the development of CTRCD. Special attention should be warranted for patients with any of these risk factors.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00520-024-09067-0. Introduction Breast cancer is the most common type of cancer in Japanese women, with more than 90,000 cases diagnosed each year [1]. However, breast cancer is a disease for which long-term survival is expected, as advances in therapy have led to a 5-year survival rate of more than 90% and many patients younger than 40 years of age are affected. Cancer therapy-related cardiac dysfunction (CTRCD) refers to myocardial damage, particularly reduced left ventricular systolic function, caused by cancer drugs. Patients treated with anthracyclines are at risk of developing CTRCD (for example, incidence of CTRCD due to doxorubicin is estimated to be 3–26%) [2], and the prognosis for anthracycline-induced CTRCD is poor [3]. It has been reported that breast cancer patients have a higher incidence of cardiovascular diseases compared to non-cancer individuals [4], and the CTRCD onset is often asymptomatic, occurring within 12 months of the initiation of anthracycline treatment [5]. Therefore, in order to identify patients who are at high risk of cardiac dysfunction, a baseline measurement of left ventricular ejection fraction (LVEF) is recommended as standard practice in any treatment regimen associated with a risk of cardiotoxic side effects [6]. Breast cancer patients who receive anthracycline treatment at our hospital are followed up in our onco-cardiology program, in which they regularly consult our cardiologist and have their cardiac function monitored [7]. To address the aim of the present study, we investigated the incidence of CTRCD in breast cancer patients treated with anthracyclines at a facility with such a monitoring program, and its possible risk factors among patient characteristics. Methods Study design This study was a single-center, retrospective study that included patients receiving treatment for breast cancer at our hospital. Eligible patients were breast cancer patients who started anthracycline treatment between January 1, 2016 and June 30, 2021, had regular consultations with cardiologists, and received LVEF assessment both before and after initiation of treatment. Age was defined as the patient’s age on the date when anthracycline treatment was started, and bodyweight was defined as the weight most recently measured before the date of initiation of anthracycline treatment. Presence of hypertension, dyslipidemia, and diabetes mellitus were determined based on the use of respective medications at the start of cancer therapy, because prescription information can be reliably verified. Smoking, alcohol consumption, and menopausal status were obtained via the standard outpatient questionnaire, filled out by the patients on their first visit. Hormone receptors status, human epidermal growth factor receptor 2 (HER2) expression, tumor lymph node metastasis (TNM) stage, laterality of cancer site treatment phase, type of chemotherapy, types of anthracyclines and anti-HER2 drugs administered, and presence or absence of radiotherapy were obtained from the patients’ medical records. Relative dose intensity (RDI) was calculated by dividing the total actual dose of anthracyclines by the total planned dose per regimen. Neutrophil/lymphocyte ratios (NLR) were calculated from laboratory values measured immediately before the start of anthracycline treatment. LVEF, cardiac troponin I (TnI), and brain natriuretic peptide (BNP) were measured before and at 3, 6, 9, and 12 months after the initiation of anthracycline treatment. The patients received one of the following chemotherapy regimens: EC (epirubicin 90 mg/m2, cyclophosphamide 600 mg/m2), FEC100/75 (fluorouracil 500 mg/m2, epirubicin 100/75 mg/m2, cyclophosphamide 500 mg/m2), AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) or CEF (cyclophosphamide 600 mg/m2, epirubicin 60 mg/m2, fluorouracil 600 mg/m2). All regimens were administered once every 3 weeks. Other anticancer drugs administered during the study period are listed in Supplemental Table 1. This study was approved by the Research Ethics Committee of Fukushima Medical University (approval number: REC2023-046) and was conducted in accordance with the Declaration of Helsinki. Since this was a retrospective study, informed consent was obtained through an opt-out method on the website of our university and no patient opted out. Echocardiography Transthoracic echocardiography was performed by a trained sonographer. LVEF was calculated using the modified biplane Simpson’s method according to the guidelines of the American Society of Echocardiography and those of the European Society of Cardiovascular Imaging [8, 9]. Definition of CTRCD CTRCD has been defined in various ways by different organizations. For example, it was defined as: a decrease in LVEF of > 10% from baseline to < 50% in the 2016 European Society of Cardiology position paper [10]; a decrease in LVEF of > 10% from baseline to < 53% in the EACVI/ASE expert consensus [11]; a decrease in LVEF of ≥ 10% from baseline to < 55% in the Cardiac Review and Evaluation Committee (CREC) criteria [12]; and a decrease in LVEF of > 10% from baseline with no definite threshold in the ESMO Clinical Practice Guidelines [13]. In the present study, we adopted the CREC criteria because it is widely used in other studies on breast cancer patients and CTRCD, allowing for direct comparisons with our data. Statistical analyses Analyses were performed using Stata/SE, version 17 (StataCorp, College Station, TX). Comparisons of patient characteristics between patients in the CTRCD and non-CTRCD groups were performed using Fisher's exact test. Odds ratios and p-values were obtained from logistic regression analysis. Analytical variables included in this analysis were age, BMI, hypertension, dyslipidemia, diabetes, smoking, alcohol consumption, ER (estrogen recepror) status, PR (progesterone receptor) status, HER2, TNM stage, menopausal status, laterality of cancer site, treatment status, type of anthracyclines administered, radiation therapy, RDI, NLR, as well as levels of TnI and BNP. Values of p < 0.05 were considered statistically signifcant; therefore, variables with these values in the univariate logistic regression analysis were subjected to multivariate logistic regression analysis in order to identify risk factors for CTRCD. Results Patients’ characteristics A total of 244 breast cancer patients started anthracyclines during the study period. Of these, 55 patients who had not consulted our cardiologist before treatment, ten who did not have baseline LVEF measurements, and two who were participating in another clinical trial were excluded, leaving 177 patients for analyses (Fig. 1). The baseline patient characteristics before anthracycline treatment are shown in Table 1. The median age was 56 years (range, 27–76 years) and all patients were female. Sixty-four (36.2%) patients had a BMI of ≥ 25 kg/m2. Thirty-seven (20.9%), 37 (20.9%), 15 (8.5%) had a history of hypertension, hyperlipidemia, and diabetes mellitus, respectively. Forty-three (24.3%), 50 (28.3%), and 19 (10.7%) reported smoking, occasional drinking, and daily drinking, respectively. The cancer sites were the right breast only in 86 (48.6%) patients, left breast only in 86 (48.6%), and both breasts in five (2.8%). Ninety-seven (54.8%) patients underwent radiation therapy. Table 1 also shows the treatment information (anti-HER2 therapy, radiotherapy and RDI).Fig. 1Consort diagram of patients included in the studyTable 1Baseline clinical characteristics of patientsVariableMedian age (range) -yr56 (27–76)Age -no.(%) < 5056(31.6) 50–6581(45.8) > 6540(22.6)Female patients -no. (%)177(100.0)BMI (kg/m2) -no. (%) < 25113(63.8) ≥ 2564(36.2)Comorbidity -no. (%) Hypertension37(20.9) Dyslipidemia37(20.9) Diabetes mellitus15(8.5)Life history -no. (%) Smoking43(24.3) Drinking Alcohol Sometimes#50(28.2) Everyday19(10.7)ER status -no. (%) Positive124(70.1) Negative53(29.9)PR status -no. (%) Positive107(60.5) Negative70(39.5)HER2 expression status -no. (%) Positive53(29.9) Negative124(70.1)TNM stage -no. (%) I36(20.3) II96(54.2) III37(20.9) IV8(4.5)Menopausal status -no. (%) Premenopausal67(37.9) Postmenopausal110(62.1)Laterality -no. (%) Right86(48.6) Left86(48.6) Both5(2.8)Treatment phase of chemotherapy -no. (%) Neoadjuvant75(42.4) Adjuvant96(54.2) Advanced6(3.4)Type of anthracyclines -no. (%) Doxorubicin9(5.1) Epirubicin168(94.9)Anti-HER2 drugs administered -no. (%)53(29.9)Radiotherapy -no. (%)97(54.8)NLR -no. (%) < 3.0134(75.7) ≥3.037(20.9) unknown6(3.4)LVEF -no. (%) < 551(0.6) 55–6586(48.6) > 6590(50.8)Troponin I, ng/ml -no. (%) ≤Reference Value168(94.9) > Reference Value2(1.1) unknown7(4.0)BNP, pg/ml -no. (%) ≤18.4130(73.4) > 18.441(23.2) unknown6(3.4)RDI -no. (%) 94 < 88(49.7) ≥9489(50.3)BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNM, tumor lymph node metastasis; NLR, neutrophil-lymphocyte ratio; LVEF, left ventricular ejection fraction; BNP, brain natriuretic peptide fraction; RDI, relative dose intensity. #: Sometimes means anything between ‘every day’ and ‘not at all’ Consort diagram of patients included in the study Table 1Baseline clinical characteristics of patientsVariableMedian age (range) -yr56 (27–76)Age -no.(%) < 5056(31.6) 50–6581(45.8) > 6540(22.6)Female patients -no. (%)177(100.0)BMI (kg/m2) -no. (%) < 25113(63.8) ≥ 2564(36.2)Comorbidity -no. (%) Hypertension37(20.9) Dyslipidemia37(20.9) Diabetes mellitus15(8.5)Life history -no. (%) Smoking43(24.3) Drinking Alcohol Sometimes#50(28.2) Everyday19(10.7)ER status -no. (%) Positive124(70.1) Negative53(29.9)PR status -no. (%) Positive107(60.5) Negative70(39.5)HER2 expression status -no. (%) Positive53(29.9) Negative124(70.1)TNM stage -no. (%) I36(20.3) II96(54.2) III37(20.9) IV8(4.5)Menopausal status -no. (%) Premenopausal67(37.9) Postmenopausal110(62.1)Laterality -no. (%) Right86(48.6) Left86(48.6) Both5(2.8)Treatment phase of chemotherapy -no. (%) Neoadjuvant75(42.4) Adjuvant96(54.2) Advanced6(3.4)Type of anthracyclines -no. (%) Doxorubicin9(5.1) Epirubicin168(94.9)Anti-HER2 drugs administered -no. (%)53(29.9)Radiotherapy -no. (%)97(54.8)NLR -no. (%) < 3.0134(75.7) ≥3.037(20.9) unknown6(3.4)LVEF -no. (%) < 551(0.6) 55–6586(48.6) > 6590(50.8)Troponin I, ng/ml -no. (%) ≤Reference Value168(94.9) > Reference Value2(1.1) unknown7(4.0)BNP, pg/ml -no. (%) ≤18.4130(73.4) > 18.441(23.2) unknown6(3.4)RDI -no. (%) 94 < 88(49.7) ≥9489(50.3)BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNM, tumor lymph node metastasis; NLR, neutrophil-lymphocyte ratio; LVEF, left ventricular ejection fraction; BNP, brain natriuretic peptide fraction; RDI, relative dose intensity. #: Sometimes means anything between ‘every day’ and ‘not at all’ Baseline clinical characteristics of patients BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNM, tumor lymph node metastasis; NLR, neutrophil-lymphocyte ratio; LVEF, left ventricular ejection fraction; BNP, brain natriuretic peptide fraction; RDI, relative dose intensity. #: Sometimes means anything between ‘every day’ and ‘not at all’ Incidence of CTRCD and its risk factors The occurrence of CTRCD during 12 months of anthracycline treatment based on LVEF is shown in Table 2. CTRCD (a decrease in LVEF ≥ 10% from baseline to < 55%) occurred in 4.5% of patients. A decrease in LVEF of > 10% from baseline to < 53% occurred in 2.8%, and a decrease of > 10% from baseline occurred in 9.6%. Comparison between the CTRCD and non-CTRCD groups showed significant differences in cancer stage before anthracycline treatment ( I, II vs. III, IV) and NLR (cutoff value of 3.0) (Table 3). A multivariate analysis between the two groups showed that cancer stage, type of anthracyclines, and NLR were strongly associated with the risk of CTRCD occurrence (Table 4).Table 2CTRCD occurrenceCTRCD DefinitionnCTRCD (%)A decrease in LVEF ≥ 10% from baseline, to a value < 55%84.5A decrease in LVEF > 10% from baseline, to a value < 53%52.8A decrease in LVEF > 10% from baseline179.6CTRCD, cancer therapy-related cardiac dysfunctionTable 3Comparison of baseline characteristics by CTRCD occurrenceVariableCTRCD (n = 8)Non-CTRCD (n = 169)p valueAge, years0.720 < 50254 50–65576 > 65139BMI, kg/m20.462 < 254109 ≥ 25460Comorbidity Hypertension2350.673 Normal blood pressure6134 Dyslipidemia1361.000 Normal lipids level7133 Diabetes mellitus2130.139 Normal blood sugar6156Life history Smoking2411.000 Non smoker6128 Drinking Alcohol0.278 Non-drinker5103 Sometimes#149 Everyday217ER status0.698 Positive5119 Negative350PR status0.714 Positive4103 Negative466HER21.000 Positive251 Negative6118TNM stage0.026 * I / II3129 III / IV540Menopausal status0.712 Premenopausal265 Postmenopausal6104Literality0.152 Right581 Left284 Both14Treatment phase of chemotherapy0.184 Neoadjuvant669 Adjuvant294 Advanced06Type of anthracyclines0.055 Doxorubicin27 Epirubicin6162Radiotherapy0.143 Received295 Not received674NLR0.040 * < 3.03131 ≥3.0433Troponin I, ng/ml1.000 ≤Reference Value8160 > Reference Value02BNP, pg/ml ≤18.461241.000 > 18.4239RDI0.72 94 < 385 ≥94584*p values < 0.05BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNM, tumor lymph node metastasis; NLR, neutrophil-lymphocyte ratio; BNP, brain natriuretic peptide fraction; RDI, relative dose intensity. #: Sometimes means anything between ‘every day’ and ‘not at all’Table 4Univariate and multivariate analyses for risk factors associated with the occurrence of CTRCDUnivariableMultivariableVariableOR95% CIp valueOR95% CIp valueAge1.780.33–9.500.60BMI1.820.44–7.530.41Comorbidity Hypertension1.280.25–6.600.78 Dyslipidemia0.530.06–4.430.53 Diabetes mellitus4.000.74–21.840.15Life history Smoking1.040.20–5.360.96 Drinking Alcohol0.420.48–3.700.35ER status0.701.61–3.040.64PR status0.640.15–2.650.54HER20.770.15–3.950.75TNM stage5.381.23–23.490.02*9.291.51–57.040.02*Menopausal status1.880.37–9.570.43Literality2.590.49–13.740.22Treatment phase type of chemotherapy0.250.48–1.250.07Type of anthracyclines0.130.22–0.760.05*0.050.06–0.470.01*Radiotherapy0.260.05–1.320.08NLR5.291.13–24.810.04*9.021.40–58.130.02*Troponin I1--BNP1.430.21–5.470.95RDI1.690.39–7.280.48*p values < 0.05BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNM, tumor lymph node metastasis; NLR, neutrophil-lymphocyte ratio; BNP, brain natriuretic peptide fraction; RDI, relative dose intensity Table 2CTRCD occurrenceCTRCD DefinitionnCTRCD (%)A decrease in LVEF ≥ 10% from baseline, to a value < 55%84.5A decrease in LVEF > 10% from baseline, to a value < 53%52.8A decrease in LVEF > 10% from baseline179.6CTRCD, cancer therapy-related cardiac dysfunction CTRCD occurrence CTRCD, cancer therapy-related cardiac dysfunction Table 3Comparison of baseline characteristics by CTRCD occurrenceVariableCTRCD (n = 8)Non-CTRCD (n = 169)p valueAge, years0.720 < 50254 50–65576 > 65139BMI, kg/m20.462 < 254109 ≥ 25460Comorbidity Hypertension2350.673 Normal blood pressure6134 Dyslipidemia1361.000 Normal lipids level7133 Diabetes mellitus2130.139 Normal blood sugar6156Life history Smoking2411.000 Non smoker6128 Drinking Alcohol0.278 Non-drinker5103 Sometimes#149 Everyday217ER status0.698 Positive5119 Negative350PR status0.714 Positive4103 Negative466HER21.000 Positive251 Negative6118TNM stage0.026 * I / II3129 III / IV540Menopausal status0.712 Premenopausal265 Postmenopausal6104Literality0.152 Right581 Left284 Both14Treatment phase of chemotherapy0.184 Neoadjuvant669 Adjuvant294 Advanced06Type of anthracyclines0.055 Doxorubicin27 Epirubicin6162Radiotherapy0.143 Received295 Not received674NLR0.040 * < 3.03131 ≥3.0433Troponin I, ng/ml1.000 ≤Reference Value8160 > Reference Value02BNP, pg/ml ≤18.461241.000 > 18.4239RDI0.72 94 < 385 ≥94584*p values < 0.05BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNM, tumor lymph node metastasis; NLR, neutrophil-lymphocyte ratio; BNP, brain natriuretic peptide fraction; RDI, relative dose intensity. #: Sometimes means anything between ‘every day’ and ‘not at all’ Comparison of baseline characteristics by CTRCD occurrence *p values < 0.05 BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNM, tumor lymph node metastasis; NLR, neutrophil-lymphocyte ratio; BNP, brain natriuretic peptide fraction; RDI, relative dose intensity. #: Sometimes means anything between ‘every day’ and ‘not at all’ Table 4Univariate and multivariate analyses for risk factors associated with the occurrence of CTRCDUnivariableMultivariableVariableOR95% CIp valueOR95% CIp valueAge1.780.33–9.500.60BMI1.820.44–7.530.41Comorbidity Hypertension1.280.25–6.600.78 Dyslipidemia0.530.06–4.430.53 Diabetes mellitus4.000.74–21.840.15Life history Smoking1.040.20–5.360.96 Drinking Alcohol0.420.48–3.700.35ER status0.701.61–3.040.64PR status0.640.15–2.650.54HER20.770.15–3.950.75TNM stage5.381.23–23.490.02*9.291.51–57.040.02*Menopausal status1.880.37–9.570.43Literality2.590.49–13.740.22Treatment phase type of chemotherapy0.250.48–1.250.07Type of anthracyclines0.130.22–0.760.05*0.050.06–0.470.01*Radiotherapy0.260.05–1.320.08NLR5.291.13–24.810.04*9.021.40–58.130.02*Troponin I1--BNP1.430.21–5.470.95RDI1.690.39–7.280.48*p values < 0.05BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNM, tumor lymph node metastasis; NLR, neutrophil-lymphocyte ratio; BNP, brain natriuretic peptide fraction; RDI, relative dose intensity Univariate and multivariate analyses for risk factors associated with the occurrence of CTRCD *p values < 0.05 BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNM, tumor lymph node metastasis; NLR, neutrophil-lymphocyte ratio; BNP, brain natriuretic peptide fraction; RDI, relative dose intensity Changes in LVEF values LVEF values at baseline, and at 3, 6, 9 and 12 months for the CTRCD and non-CTRCD groups are shown in Fig. 2. LVEF in the CTRCD group began to decline at 3 months and were still declining at 12 months. Significant differences were observed between LVEF values of the two groups at 3, 6, and 12 months. The progression of these differences from baseline to each time point is also shown in Fig. 3. Differences from baseline were analyzed because we suspected the possibility that the LVEF values of the two groups were already different at baseline. Compared to the non-CTRCD group, the CTRCD group showed a greater decline from baseline at 6 months than the non-CTRCD group and no recovery was observed at 12 months. However, none of the differences at each time point were statistically significant.Fig. 2Median LVEF at baseline and at 3, 6, 9, 12 months, stratified by whether the patient met our criteria for CTRCD at any time point during the study period. *p < 0.05Fig. 3Difference in Median LVEF from baseline at 3, 6, 9, and 12 months, stratified by whether the patient met our criteria for CTRCD at any time point during the study period Median LVEF at baseline and at 3, 6, 9, 12 months, stratified by whether the patient met our criteria for CTRCD at any time point during the study period. *p < 0.05 Difference in Median LVEF from baseline at 3, 6, 9, and 12 months, stratified by whether the patient met our criteria for CTRCD at any time point during the study period The time courses of LVEF changes in the eight patients who developed CTRCD are shown in Fig. 4. The large dots represent the LVEF values that match the current study’s definition of CTRCD. At the beginning of anthracycline treatment, all eight patients had LVEF values > 55%, but at 3 months, two patients showed a decline to a level that met the definition of CTRCD. Another four patients showed a decline to that level at 6 months, three of whom were still experiencing a decline at 12 months.Fig. 4LVEF at baseline and at 3, 6, 9, and 12 months in 8 patients who developed CTRCD LVEF at baseline and at 3, 6, 9, and 12 months in 8 patients who developed CTRCD BNP and TnI Laboratory values for BNP and TnI were investigated; both test values were significantly elevated in the CTRCD group at 6 months compared to the non-CTRCD group (Supplemental Figs. 1 and 2). Discussion In the present study, we investigated the incidence of CTRCD in breast cancer patients treated with anthracyclines and found that 4.5% of the patients developed CTRCD, with risk factors strongly related to the pre-treatment cancer stage, type of anthracycline administered, and NLR. The incidence of CTRCD in this study was lower than those reported in previous studies on CTRCD in anthracycline-treated breast cancer patients that used the same criteria for CTRCD [14–17]. Other previous studies reported that risk factors for anthracycline-induced CTRCD in breast cancer patients were the baseline LVEF and pre-existing conditions such as hypertension, dyslipidemia, and diabetes [18–20]. A possible reason for the lower incidence in the present study is that pre-existing conditions were well-controlled by medication at the start of anthracycline treatment. In addition, physicians tend not to choose treatment that includes anthracyclines in breast cancer patients with LVEF of < 50%. These factors may have contributed to the lower incidence of CTRCD in the present study compared to previous reports. The present study revealed a higher incidence of CTRCD in stages III and IV compared to stages I and II. The median total doses of doxorubicin equivalent per patient in the stage III and IV patients (180.0 mg/m2) was almost identical to that of the stage I and II patients (177.4 mg/m2). However, among the stage III and IV patients, the total dose of doxorubicin was higher in the CTRCD group (306.3 mg/m2) than that in the non-CTRCD group (179.4 mg/m2), indicating that the total dose may have contributed to the occurrence of CTRCD in the stage III and IV patients. In the treatment of advanced breast cancer, a greater number of treatment cycles are likely to be performed than in the treatment of early-stage breast cancer. Therefore, cancer stage was identified as one of the risk factors for the occurrence of CTRCD. However, there was no difference between the CTRCD group and the non-CTRCD group at 180.0 mg/m2 and 177.4 mg/m2 in the stage I and II patients. This suggests that total dose is not the only factor involved in the development of CTRCD in early-stage patients. Although it is known that the incidence of CTRCD with anthracycline treatment increases with total dose [21], total dose was not included in the analysis because the incidence of CTRCD in this study focused on the clinical factors of the patients before treatment initiation. Anthracyclines increase the production of free radical species that affect cell membranes, induce mitochondrial damage, alter ATP production, and cause cell apoptosis [22]. Doxorubicin was the first anthracycline-based anti-cancer drug, followed by its analog, epirubicin, through a prospective randomized comparison has been reported that these two drugs have comparable anti-tumor effects with a lower risk of cardiac dysfunction [23]. In the present study, the type of anthracycline was a risk factor for CTRCD, and doxorubicin showed a higher CTRCD incidence than epirubicin. NLR is elevated due to changes in relative counts of neutrophils and lymphocytes that occur as part of the systemic inflammatory response induced by cancer [24–26]. Prognostic relevance of NLR in breast cancer has been reported in multiple previous studies [27–29]. This can be attributed to the difference in the roles played by lymphocytes and neutrophils: the former mediates immune response to neoplasm development and proliferation, while the latter promotes cancer development [30–33]. Regarding the association between NLR and cardiovascular disease, higher NLR levels have been reported to be associated with lower LVEF. Relative neutrophilic increases reflect a physiological state of systemic inflammation, which promotes the generation of oxygen-free radicals, perpetuating myocardial tissue damage. Furthermore, lymphopenia, promoted by elevated cortisol levels due to physiological stress, has been reported to promote apoptosis of cardiac cells [34]. In the current study, we set a cutoff value of 3 for NLR based on previous studies that assessed overall survival of breast cancer patients [35], and our results are consistent with these reports. Increased blood levels of BNP and TnI have been shown to be indicators of early detection of anthracycline-induced cardiac dysfunction [36, 37]. Our results confirmed that both of the two test values were significantly elevated at 6 months in the CTRCD group compared to the non-CTRCD group. However, statistical analysis was not performed due to the limited sample size and the skewed distribution of the data. A limitation of the present study is the low incidence rates of CTRCD. In addition, the study was conducted at a single institution, resulting in a relatively small study population. Although a higher uniformity of treatment and patient management, as well as the consistent testing methodology, are advantages of a single-center study, further studies with larger numbers of patients and institutions in a prospective cohort study design are warranted. In conclusion, 4.5% of the breast cancer patients treated with anthracyclines experienced a reduction in LVEF to the levels that met the definition of CTRCD within the first year of treatment. The risk factors for CTRCD were identified as advanced cancer stage and having higher NLR at the start of anthracycline treatment. The administration of doxorubicin is also associated with the onset of CTRCD, compared to epirubicin. This information may contribute to improving a risk prediction model for the occurrence of CTRCD in breast cancer patients who underwent anthracycline treatment. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (PPTX 132 KB)Supplementary file2 (DOCX 19 KB) Supplementary file1 (PPTX 132 KB) Supplementary file2 (DOCX 19 KB)